RET and lung carcinoma: For example, cabozantinib was studied in RET-rearranged lung cancers [10] and showed an overall response rate (ORR) of 28% (95% CI: 12–49), with progression free survival (PFS) of 5.5 months (95% CI: 3.8–8.4).